



**ISPOR Russia St. Petersburg Chapter**

**Annual Report 2022**

To: Board of Directors

International Society for Pharmacoeconomics and  
Outcomes Research

505 Lawrence Square Boulevard

South Lawrenceville, TO 08648 USA

**PREPARED BY**

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University; chief editor of the journal “Real-World Data and Evidence”

Yulia E. Balykina, PhD, associate professor, St Petersburg State University, faculty of Applied Mathematics and Control Processes.

**President of ISPOR Russia St. Petersburg Regional Chapter**

Alexey S. Kolbin, MD, PhD, Doctor of Science, Professor, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University, St. Petersburg, Russia; chief editor of the journal “Real-World Data and Evidence”

**President-Elect**

Sergey K. Zyryanov, MD, PhD, Professor, Head of the Department of Clinical Pharmacology of the RUDN University, Moscow, Russia; chief editor of the “Good clinical practice” journal

**Executive Director**

Dmitry Yu. Belousov, Science Editor of the “Good clinical practice”, “Real-World Data & Evidence”; General Director of Center for Pharmacoeconomic Research, Moscow, Russia

**Secretary**

Alexey A. Kurylev, MD, Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

## Activities of the Chapter in 2022:

### I. Publications in the Field of Pharmacoeconomics and Health Technology Assessment

№	Title	Journal	Authors
1	Estimating the indirect costs associated with psoriasis	Kazan medical journal. 2022;103(5):824-831. DOI: <a href="https://doi.org/10.17816/KMJ2022-824">10.17816/KMJ2022-824</a>	Novoderezhkina E.A., Zyryanov S.K.
2	Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation	Terapevticheskii arkhiv. 2022;94(7):850-858. DOI: <a href="https://doi.org/10.26442/00403660.2022.07.201715">doi.org/10.26442/00403660.2022.07.201715</a>	Zyryanov S.K., Dyakov I.N., Aisanov Z.R.
3	Safety of antithrombotic therapy in elderly patients: analysis of the Russian Pharmacovigilance Database	Surgeon. 2022;3:51-59. DOI:10.33920/med-15-2203-05	Zatolochina K.E., Zyryanov S.K., Ushkalova E.A.
4	Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(2):188-198. DOI: <a href="https://doi.org/10.17749/2070-4909/farmakoeconomika.2022.144">10.17749/2070-4909/farmakoeconomika.2022.144</a>	Zyryanov S.K., Dyakov I.N.
5	The role of real world data and real world evidence in health technology assessment	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(3):380-389. DOI: <a href="https://doi.org/10.17749/2070-4909/farmakoeconomika.2022.120">10.17749/2070-4909/farmakoeconomika.2022.120</a>	Novoderezhkina E.A., Zyryanov S.K.
6	Actual questions of increasing the availability of innovative therapy and the organization of medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Advisory Board	The Journal of Atherosclerosis and Dyslipidemias. 2022;4(49):54-61. DOI: <a href="https://doi.org/10.34687/2219-8202.JAD.2022.04.0006">10.34687/2219-8202.JAD.2022.04.0006</a>	Sergienko I.V., Nedogoda S.V., Vertkin A.L., Glezer M.G., Gurevich V.S., Gornyakova N.B., Babkova N.V., Zhuravleva M.V.,

			Zyryanov S.K., Kosmacheva E.D., Ryazhenov V.V., Shalnova S.A., Frolov M.Y., Ezhov M.V.
7	Current patient safety issues: the role of pharmacovigilance	Public Health. 2022;2(3):25-34. DOI: 10.21045/2782-1676-2021-2-3-25-34	Zyryanov S.K., Zatolochina K.E., Kazakov A.S.
8	Cost effectiveness and budget impact of universal varicella vaccination in Russia	Hum Vaccin Immunother. 2022 Nov 30;18(5):2045152. DOI: 10.1080/21645515.2022.2045152.	Marijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A, Tatochenko V, Briko N.
9	Cost-Effectiveness of Pneumococcal Vaccination among Patients with Diabetes Mellitus	Epidemiology and Vaccinal Prevention. 2022;21(5):78-88. DOI: 10.31631/2073-3046-2022-21-5-78-88	Rudakova A.V., Briko N.I., Lobzin Yu.V., Namazova-Baranova I.S., Avdeev S.N., Korshunov V.A., Kostinov M.P., Ignatova G.I., Blinova E.V., Kontsevaya A.V., Shepel R.V., Drozdova I.Yu., Drapkina O.M.
10	Cost-effectiveness of pentavalent rotavirus vaccination in the Russian Federation	Journal Infectology. 2022;14(5):69-77. DOI: 10.22625/2072-6732-2022-14-5-69-77	Rudakova A.V., Kharit S.M., Rychkova S.V., Lobzin Yu.V.
11	Pharmacoeconomic Analysis of Gilteritinib in the Therapy of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Mutation	Clinical oncohematology. 2022;15(1):85–96. DOI: 10.21320/2500-2139-2022-15-1-85-96	Kolbin A.S., Gomon Yu.M., Balykina Yu.E., Proskurin M.A.
12	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults	Good Clinical Practice. 2022;(1):4-16. DOI: 10.37489/2588-0519-2022-1-4-16	Kolbin A.S., Kurilev A.A., Balikina Y.E., Proskurin M.A.

<b>13</b>	Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults	Good Clinical Practice. 2022;(1):17-29. DOI: 10.37489/2588-0519-2022-1-17-29	Kolbin A.S., Gomon Y.M., Proskurin M.A., Balikina Y.E.
<b>14</b>	Reporting of drug adverse reactions during treatment of COVID-19 in the Russian Federation and the United States	Clinical Pharmacology and Therapy. 2022;31(1): 91-96 DOI 10.32756/0869-5490-2022-1-91-96	Sirayeva G.I., Kolbin A.S., Sergeeva T.A., Mishinova S.A.
<b>15</b>	The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):87-105. DOI: 10.17749/2070-4909/farmakoekonomika.2022.107	Kolbin A.S., Gomon Yu.M., Kasimova A.R., Kurylev A.A., Bem A.E.
<b>16</b>	A systematic review of real-world clinical practice data in COVID-19: non-interventional studies	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):145-161. DOI: 10.17749/2070-4909/farmakoekonomika.2022.099	Mishinova S.A., Gomon Yu.M., Kolbin A.S., Strizheletsky V.V., Ivanov I.G.
<b>17</b>	External control during RWD/RWE research: a methodological approach	Good Clinical Practice. 2022;(2):21-27. DOI: 10.37489/2588-0519-2022-2-21-27	Zhuravkov A.A., Kolbin A.S.
<b>18</b>	Problems of assessing economic effectiveness of antimicrobial agents: an experience of the Russian Federation	Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):23-29. DOI: 10.36488/cmac.2022.1.23-29	Gomon Yu.M., Kolbin A.S.
<b>19</b>	Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(3):320-331. DOI: 10.17749/2070-4909/farmakoekonomika.2022.149	Strizheletsky V.V., Gomon Yu.M., Spichakova E.A., Kolbin A.S., Kalyapin A.A., Makarov S.A., Lomiya A.B., Sultanova F.M.

<b>20</b>	New Technologies in Electronic Pharmacovigilance Systems for Marketing Authorisation Holders	Safety and Risk of Pharmacotherapy. 2022;10(3):230-239. DOI: 10.30895/2312-7821-2022-10-3-230-239	Loginovskaya O.A., Kolbatov V.P., Sukhov R.V., Ryavkina M.S., Kolbin A.S.
<b>21</b>	The socioeconomic burden of paracetamol adverse reactions over 10 years in Russia	Clinical Pharmacology and Therapy. 2022;31(3):60-66 DOI 10.32756/0869-5490-2022-3-60-66	Sirayeva G.I., Kolbin A.S., Kalyapin A.A., Balykina Y.E.
<b>22</b>	Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity	Oncohematology. 2022;17(4):196-204. DOI: 10.17650/1818-8346-2022-17-4-196-204	Kasimova A.R., Kolbin A.S., Proskurin M.A., Balykina Yu.E.
<b>23</b>	Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years	Good Clinical Practice. 2022;(3):19-30. DOI: 10.37489/2588-0519-2022-3-19-30	Syraeva G.I., Kolbin A.S., Mishinova S.A., Kalyapin A.A.
<b>24</b>	Pharmacoeconomic substantiation of the protocol for the use of fosfomycin for the sanitation of the urinary tract of patients before arthroplasty of large joints	Clinical microbiology and antimicrobial chemotherapy. 2022;24(S1):42-43	Tufanova O.S., Kasimova A.R., Bozhkova S.A., Rukina A.N., Gordina E.M.
<b>25</b>	Pharmacoeconomic study of the use of fosfomycin and fluoroquinolones for urinary tract sanitation in orthopaedic patients	Therapy. 2022;4(56):62-70. DOI: 10.18565/therapy.2022.4.62-70	Tufanova O.S., Kasimova A.R., Gordina E.M., Rukina A.N., Bozhkova S.A.
<b>26</b>	A brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU)	Real-World Data & Evidence. 2022;2(1):1-9. DOI: 10.37489/2782-3784-myrd-6	Kolbin A.S., Belousov D.Yu.
<b>27</b>	Chinese experience on using RWE to support drug research, development and evaluation	Real-World Data & Evidence. 2022;2(1):17-27. DOI: 10.37489/2782-3784-myrd-8	Kolbin A.S., Belousov D.Yu.
<b>28</b>	Real-world evidence market: key players and key segments	Real-World Data & Evidence. 2022;2(1):40-43. DOI:	Kasimova A.R., Kolbin A.S.

		10.37489/2782-3784-myrd-11	
<b>29</b>	Resolution based on the results of the III annual scientific and practical conference «Real clinical practice in a changing world. Challenges and Solutions»	Real-World Data & Evidence. 2022;2(3):35-41. DOI: 10.37489/2782-3784-myrd-20	Kolbin A.S.
<b>30</b>	Combining real-world data with randomized controlled trials results in better information oncology decision making	Real-World Data & Evidence. 2022;2(2):21-31. DOI: 10.37489/2782-3784-myrd-14	Usmanova T.A., Verbitskaya E.V.
<b>31</b>	Introduction of modern analytical systems into the practice of a doctor. Experience of the federal state Institute of oncology named after N.N. Petrov of the ministry of health of Russian Federation	Quality management in medicine, 2022;1:64-70	Komarov Yu.I., Khrapovitskaya E.Yu., Kurylev A.A., Lazukov V.V., Evseenko E.N., Belyaev A.M.
<b>32</b>	Analysis of RWD/RWE recommendations and guidelines for 2021. International experience on the example of USA	Real-World Data & Evidence. 2022;2(3):1-6. DOI: 10.37489/2782-3784-myrd-17	Kurylev A.
<b>33</b>	Assessment of the Pharmaco-economic and Pharmacoepidemiological Consequences of the Adoption of the Clinical Decision Support System (CDSS) Components in a Surgical Hospital Using the ACT / DDD Methodology	Value in Health, 2022;25(1):S153. DOI: 10.1016/j.jval.2021.11.742	Kolbin A., Velum I., Balykina Y., Proskurin M.
<b>34</b>	Pharmaco-economic Analysis of the Use of Antiretroviral Drugs Based on Local Data of Real Clinical Practice and State Drug Provision of HIV-Infected People in the Russian Federation	Value in Health, 2022;25(1):S41. DOI: 10.1016/j.jval.2021.11.189	Kolbin A., Velum I., Balykina Y., Proskurin M.
<b>35</b>	A Systematic Review of Real-World Clinical Practice Data in COVID-19: Non-Interventional Studies	Value in Health, 2022;25(1):S270. DOI: 10.1016/j.jval.2021.11.1314	Mishinova S., Gomon, J. Kolbin A.,

			Strizheletsky V., Ivanov I.
36	The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy	Value in Health, 2022;25(1):S68. DOI: 10.1016/j.jval.2021.11.315	Kolbin A., Kurylev A., Balykina Y., Proskurin M., Mishinova S.
37	Analysis of the National Database of the Russian Federation on the Safety of Medicines for Etiopathogenetic Treatment covid-19 in Clinical Practice (REAL-WORLD DATA; RWD)	Value in Health, 2022;25(7):S587. DOI: 10.1016/j.jval.2022.04.1585	Kolbin A., Syraeva G., Mishinova S.
38	A Real-World Pharmacovigilance Study Using National Russian Database of Adverse Events of COVID-19-Related Drugs: Focus on Hydroxychloroquine	Value in Health, 2022;25(7):S593. DOI: 10.1016/j.jval.2022.04.1615	Kolbin A., Mishinova S., Syraeva G., Polushin Y.
39	Pharmacoeconomic and Pharmacoepidemiological Analysis of the Use of Drugs in an Anti-Tuberculosis Hospital Based on the Local Real-World Data	Value in Health, 2022;25(7):S394. DOI: 10.1016/j.jval.2022.04.554	Kolbin A., Velum I., Balykina Y., Pantelev Y., Proskurin M.
40	Pharmacoeconomic and Pharmacoepidemiological Analysis of Changes in the Practice of Perioperative Antibiotic Prophylaxis in a Multi-Specialty Surgical Hospital Based on the Local Real-World Data	Value in Health, 2022;25(7):S374. DOI: 10.1016/j.jval.2022.04.456	Kolbin A., Velum I., Balykina Y., Proskurin M.
41	The effectiveness of on-line hemodiafiltration in patients with chronic kidney disease: risk factors and improving the assessment of fluid excretion values	Nephrology. 2022;26(1):57-68. DOI: 10.36485/1561-6274-2022-26-1-57-68	Zarya Y.V., Gurevich K.Y., Plavinskii S.L.
42	Approaches to forecasting of time dynamics of the processes and use of Farr's epidemic evolution law on example of dynamics of new cases of HIV-infection in Russian Federation	HIV Infection and Immunosuppressive Disorders. 2022;14(1):90-99. <a href="https://doi.org/10.22328/2077-9828-2022-14-1-90-99">https://doi.org/10.22328/2077-9828-2022-14-1-90-99</a>	Barinova A.N., Lebedeva A.A., Gusarov M.V., Plavinskii S.L.

43	Study of the effect of using a foam form with ceramides and a cholesterol-phytosterol complex in patients with atopic dermatitis. Pediatrics	Consilium Medicum. 2022;3:230–238. DOI: 10.26442/26586630.2022.3.201825	Zaslavsky D.V., Barinova A.N., Plavinskij S.L., Zelianina M.I., Manylova E.S.
44	STaRT-RWE: structured template for planning and reporting on the implementation of real-world evidence studies	Real-World Data & Evidence. 2022;2(3):20-34. DOI: 10.37489/2782-3784-myrwd-19	Plavinskij S.L., Barinova A.N.
45	Forecasting a New Type of Virus Spread: A Case Study of COVID-19 with Stochastic Parameters	Mathematics 2022, 10, 3725. DOI: <a href="https://doi.org/10.3390/math10203725">10.3390/math10203725</a>	Zakharov V., Balykina Y., Ilin I., Tick A.
46	Possible approaches to the implementation of technological solutions in unified eHealth member countries of the EAEU	Manager of Health Care, 2022;3:60-69	Akulin I.M., Chesnokova E.A., Presnyakov R.A., Balykina Yu.E., Svirkin M.V., Guryanova N.E.
47	Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study	Value in Health. 2022;25(12):S207	Kolbin A., Gomon J., Balykina Y., Spichakova E., Kalyapin A., Lomiya A.
48	A Systematic Review and Meta-Analysis of the Janus Kinase Inhibitors Safety Profile in Relation to the Risks of Secondary Bacterial Infections	Value in Health. 2022;25(12):S327–S328	Kolbin A., Gomon J., Balykina Y., Sultanova F.
49	A Systematic Review of the Safety of COVID-19 Anti-Interleukin Therapy	Value in Health. 2022;25(12):S328	Kolbin A., Gomon J., Balykina Y., Sultanova F.
50	Ethical review of real-world study	Real-World Data & Evidence. 2022;2(2):41-44. DOI: 10.37489/2782-3784-myrwd-16	Volskaya E.A., Khokhlov A.L., Belousov D.Yu.
51	3D bioprinting: issues of bioethics	Medical Ethics. 2022;(1):41–5. DOI: 10.24075/medet.2022.040	Khokholov A.L., Belousov D.Y.



<b>52</b>	Bioethical Aspects of Translational Medicine	Kutafin Law Review. 2022;9(1):175-190. DOI: <a href="https://doi.org/10.17803/2313-5395.2022.1.19.175-190">10.17803/2313-5395.2022.1.19.175-190</a>	Khokhlov A.L., Belousov D.Yu., Kagramanyan I.N., Mokhov A.A., Tsyzman L.G., Samarina E.I.

## II. Oral and Poster Presentations on Pharmacoeconomics and Health Technology Assessment at the ISPOR International and European Meetings

<b>№</b>	<b>Conference Title</b>	<b>Organizers</b>	<b>Report Title</b>	<b>Date</b>	<b>Venue</b>
<b>1</b>	Virtual ISPOR Annual 2022	ISPOR	Pharmacoeconomic and Pharmacoepidemiological Analysis of the Use of Drugs in an Anti-Tuberculosis Hospital Based on the Local Real-World Data	May 16-18, 2022	Virtual
<b>2</b>	Virtual ISPOR Annual 2022	ISPOR	Pharmacoeconomic and Pharmacoepidemiological Analysis of Changes in the Practice of Perioperative Antibiotic Prophylaxis in a Multi-Specialty Surgical Hospital Based on the Local Real-World Data	May 16-18, 2022	Virtual
<b>3</b>	Virtual ISPOR Europe 2022	ISPOR	A Systematic Review and Meta-Analysis of the Janus Kinase Inhibitors Safety Profile in Relation to the Risks of Secondary Bacterial Infections	November 2022	Virtual
<b>4</b>	Virtual ISPOR Europe 2022	ISPOR	A Systematic Review of the Safety of COVID-19 Anti-Interleukin Therapy	November 2022	Virtual
<b>5</b>	Virtual ISPOR Europe 2022	ISPOR	Pharmacotherapy of Obesity in the Russian Federation:	November 2022	Virtual

			Pharmacoepidemiological Study		
--	--	--	----------------------------------	--	--

### III. Oral Presentations in the Field of Pharmacoeconomics and Health Technology Assessment at Russian and International Conferences

№	Conference Title	Organizers	Report Title	Dates	Venue
1	VIII St. Petersburg International Oncology Forum «White Nights 2022». Association of Oncologists of the Northwestern Federal District	Association of oncologists of the North-West	Zyryanov S.K. Real clinical practice in oncology: focus on safety	27.06-03.07.2022	St. Petersburg
2	III Joint Congress of NSPHO and RSPO “Current Problems and Prospects for the Development of Pediatric Oncology and Hematology in the Russian Federation – 2022”	Russian Medical Academy of Continuous Professional Education (RMACPE)	Zyryanov S.K. What is important to know about biotech medicines	24.11-26.11.2022	Moscow
3	World Patient Safety Day: “Medication without harm”	RMACPE	Zyryanov S.K. Organization of drug therapy safety monitoring in a medical organization	17.09.2022	Moscow
4	III Annual Conference “Real World Data in a Changing World. Challenges and Solutions”	Association of Specialists in HTA, Association of Clinical Pharmacologists, ISPOR St. Petersburg Chapter	Zyryanov S.K. Real clinical practice of pathogenetic therapy of spinal muscular atrophy	29.09.2022	Moscow
5	VII All-Russian Congress All-Russian Congress of	Association of Cancer Patients	Zyryanov S.K. Discussion of the issue:	19.10-21.10.2022	Moscow

	Oncopatients. Association of Cancer Patients “HELLO!”		original drugs vs biosimilars		
6	Club of specialists in pneumococcal infections “Immunological aspects of vaccination against pneumococcal infection” (www.pneumoclub.ru)		Rudakova A.V. Pharmacoeconomic aspects of vaccine prevention of pneumococcal infection	09.02.2022	Moscow
7	All-Russian Vaccination Assembly “Protecting Generations”	The Union of Pediatricians of Russia	Rudakova A.V. Arguing the need for vaccination against pneumococcal infection for the state and society	March 5, 2022	Moscow
8	III International Conference “Rational Use of Innovative Medicines in Practical Medicine”	Professional Association of Clinical Pharmacologists and Pharmacists	Kolbin A.S. RWD in the Russian Federation, prospects for the EAEU	April 5, 2022	Kazan
9	Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices	The First Pavlov State Medical University of St. Petersburg	Kolbin A.S. Analysis of the safety of NSAIDs in Russia according to the national pharmacovigilance database	April 18, 2022	St. Petersburg
10	All-Russian meeting and XIII All-Russian scientific conference with international participation “Current issues of clinical pharmacology and drug supply”	Association of Clinical Pharmacologists of the Russian Federation	Kolbin A.S. The concept of RWD / RWE in the EAEU and the Russian Federation: initiatives from clinical pharmacology	May 18, 2022	Moscow
11	V All-Russian scientific conference with international participation “Safety of pharmacotherapy: Noli nocere!”	RMACPE	Kolbin A.S. RWD and pharmacovigilance	May 19, 2022	Moscow

12	Drug Safety Forum at SPIEF2022		Kolbin A.S. RWD / RWE: real world data as a tool for making decisions on the advisability of reimbursement of drug costs	June 15, 2022	St. Petersburg
13	IX International Scientific Conference “Health Technology Assessment: Improving the Strategy for the Development of the Drug Supply System”	MH RF	Kolbin A.S. Prospects for the HTA development	June 20, 2022	Moscow
14	RWD / RWE Symposium – new horizons for development in Russia within the framework of the VIII St. Petersburg International Oncology Forum «White Nights 2022»	Association of Oncologists of the Northwestern Federal District	Kolbin A.S. RWD / RWE – from glossary to practical implementation	June 27, 2022	St. Petersburg
15	RWD / RWE Symposium – new horizons for development in Russia within the framework of the VIII St. Petersburg International Oncology Forum «White Nights 2022»		Kolbin A.S. RWE/RWD research in oncology – where are we now?	June 29, 2022	St. Petersburg
16	Strategic session “Introduction of RWE into the practice of health technology assessment in the Russian Federation”		Kolbin A.S. RWD, RWE: Current situation in the Russian Federation	July 25, 2022	Moscow
17	World Patient Safety Day: Medicine Without Harm	RMACPE	Kolbin A.S. Socioeconomic Burden of Adverse Reactions	September 17, 2022	Moscow

18	Real World Data in a Changing World. Challenges and Solutions		Kolbin A.S. Current state of RWD / RWE in Russia	September 29, 2022	Moscow
19	Russian National Congress of Cardiology (RNCC) with international participation “Cardiology 2022: a new strategy in the new reality - openness, unity, sovereignty”	MH RF	Kolbin A.S. The potential of using RWD in evaluating innovative methods of treating dyslipidemia and other cardiovascular diseases in the Russian Federation	October 1, 2022	Kazan
20	“Right to Health” Congress. Symposium: New solutions in healthcare: digitalization and high technologies as a way to optimize		Kolbin A.S. The RWD / RWE concept in Russia. Where are we now?	October 20, 2022	Moscow
21	All-Russian scientific conference “Drug supply in the Russian Federation. Is the system ready for new challenges?”		Kolbin A.S. World experience in the use of RWD to support decision-making by regulatory authorities	November 25, 2022	Moscow
22	All-Russian Congress on continuing professional medical education of health workers "HEST: health, education, science, technology". Innovations in oncohematology and drug treatment of breast cancer	RMACPE	Kolbin A.S. RWD / RWE in oncology: from a glossary to the possibility of application	December 2, 2022	Moscow
23	IX All-Russian Conference with international participation “Current issues of preclinical and clinical studies of drugs, biomedical cell products		Mishinova S.A. COVID-19 in real clinical practice, results of a retrospective cohort study	April 18-19, 2022	St. Petersburg

	and clinical trials of medical devices”				
24	IX Interregional scientific symposium with international participation “Pharmacoeconomics of viral infections”	North-West District Center for the Prevention and Control of AIDS of the St. Petersburg Research Institute	Mishinova S.A. Report on data from the national database on adverse events of drugs used in the new coronavirus infection	April 21, 2022	St. Petersburg
25	V All-Russian scientific and practical conference with international participation “Safety of pharmacotherapy: Noli nocere!”	RMACPE	Mishinova S.A. Report on data from the national database on adverse events of drugs used in the new coronavirus infection	May 19, 2022	St. Petersburg
26	XVII International Congress “Rational pharmacotherapy “Golden Autumn”	Association of Clinical Pharmacologists of St. Petersburg	Tufanova O.S. Pharmacoeconomic substantiation of the use of fosfomycin for the sanitation of the urinary tract in patients before arthroplasty of large joints	October 13-15, 2022	St. Petersburg
27	XIX Russian Conference with international participation “Malignant lymphomas”	RMACPE	Kasimova A.R. Pharmacoeconomic analysis of the use of fixed-duration targeted therapy schemes for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity	October 26–28, 2022	Moscow
28	IX Interregional scientific symposium with international participation “Pharmacoeconomics of viral infections”		Gomon Yu.M. Socio-economic burden of COVID-19 in the Russian Federation. What's new?	April 21, 2022	St. Petersburg

29	July dews: a refreshing seminar for clinical pharmacologists	Association of Clinical Pharmacologists	Gomon Yu.M. Pharmacoepidemiology of obesity in Russia	June 30, 2022	Volgograd
30	RWD/RWE Symposium: new horizons for development in Russia as part of the VIII St. Petersburg International Oncology Forum «White Nights 2022»	Association of Oncologists of the Northwestern Federal District	Kurylev A.A. Features of real world data collection in the treatment of patients with malignant neoplasms	June 27, 2022	St. Petersburg
31	Real World Data in a Changing World. Challenges and Solutions		Kurylev A.A. Real world data sources of data from real practice of drug therapy of malignant neoplasms	September 29, 2022	Moscow
32	Association of Oncologists of the North-West		Kurylev A.A. Assessment of the need for anticancer drugs using data from information systems	October 7, 2022	Murmansk
33	Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices		Plavinsky S.L. Planning for conducting and processing the results of RWD studies: the concept of a targeted trial	April 19, 2022	St. Petersburg
34	IX Interregional scientific symposium with international participation “Pharmacoeconomics of viral infections”		Plavinsky S.L., Lebedeva A.A. Estimating the cost of an HIV infection for a simplified cost-benefit analysis	April 21, 2022	St. Petersburg
35	Symposium: “Real-life clinical research in oncology – where are we now?” within the framework of the VIII St. Petersburg International	Association of Oncologists of the Northwestern Federal District	Plavinsky S.L. Can we trust RWE/RWD research?	June 29, 2022	St. Petersburg

	Oncology Forum «White Nights 2022»				
36	III annual scientific conference with international participation “Real World Data in a Changing World. Challenges and Solutions”		Plavinsky S.L. Survival analysis: how to avoid common mistakes in the study of medical health records and databases? Dialogue between biostatistician and clinician	September 29, 2022	Moscow
37	Conference dedicated to the 25th anniversary of the Russian Family Doctor Journal		Plavinsky S.L. Clinical guidelines and real world data - never happened and here again?	October 20, 2022	St. Petersburg
38	AIPM Educational Project “Using Real World Data”		Plavinsky S.L. Limitations of RWD and approaches to overcome them	December 16, 2022	Online

#### IV. ISPOR Chapter Journal

1. Good Clinical Practice. [www.clinvest.ru](http://www.clinvest.ru)
2. Real-World Data & Evidence [www.myrwd.ru/jour](http://www.myrwd.ru/jour)

#### V. Branch Interaction with Authorities

1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health
2. Participation in the Committee of the Ministry of Health of the Russian Federation on the formation of restrictive drug lists of the Ministry of Health of the Russian Federation.
3. Participation in the Working group on the formation general approaches to drug regulation within the framework of the Eurasian Economic Union.
4. Development of the Concept for the Development of Approaches to the Collection, Analysis and Use of Real World Data in the Member States of the Eurasian Economic Union (RWD / RWE).
5. Participation in the Working group of experts of the Ministry of Health of the Russian Federation on the issues of immunoprophylaxis of infectious diseases.

#### VI. Chapter Interaction with Professional Organizations

1. Participation in the work of the All-Russian Association of Clinical Pharmacologists



2. Participation in the work of the Educational and Methodical Committee on Clinical Pharmacology under the Russian Federation Ministry of Health

## VII. Chapter Websites

- <http://www.labelinpharm.ru>
- <http://www.healtheconomics.ru>
- YouTube channel:  
<https://www.youtube.com/playlist?list=PLrajN8RdEIYoRDKBcWVdhyawjsTJ8rUIQ>

## VIII. Educational Programs and Seminars

1. On the basis of the Pavlov First Saint Petersburg State Medical University, an educational cycle for doctors was organized within the framework of continuing medical education (the cycle information is posted on the Continuing Medical and Pharmaceutical Education Portal (<http://edu.rosminzdrav.ru/>): “Current Issues of Health Technology Assessment”, October 2022.
2. An elective course “Fundamentals of Pharmacoeconomics” for the 5<sup>th</sup> year students of the pharmaceutical faculty of the St. Petersburg State Chemical and Pharmaceutical University (SPCPA), and elective course “Pharmacoeconomics of innovative drugs” for students of the Master’s degree program for the “Biotechnology” specialty in SPCPA are organized annually.
3. At the North-West State Medical University named after I.I. Mechnikov, the module “Health Technology Assessment” is organized annually for students of the master's program with major in Public Health.

## IX. Organizational Work

1. Within the framework of the IX All-Russian conference with international participation “Current issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices”, the section “RWD / RWE” was organized and held on April 19, 2022.
2. Within the framework of the IX All-Russian conference with international participation “Current issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices”, the Pharmacovigilance section was organized and held on April 18, 2022.
3. IX Interregional Scientific Symposium with international participation “Pharmacoeconomics of Viral Infections” was organized and held on April 21, 2022.
4. As part of the VIII St. Petersburg International Oncology Forum “White Nights – 2022” The Symposium “RWD / RWE – new horizons for development in Russia”, was organized and held on June 27, 2022.
5. III Annual Scientific Conference with international participation “Real World Data in a Changing World. Challenges and Solutions” was organized and held on September 29, 2022.

## X. Chapter Plans for the Future

1. Development of recommendations “General approaches to obtaining, analyzing and using RWD in the life cycle of a medicinal product” within the framework of the Eurasian Economic Union.
2. Preparation and publication of a study guide: RWE/RWD Studies, 2023